A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study

Inclusion Criteria: 1. A healthy adult man aged between 20 and 45 years (inclusive) at screening 2. Weight between 55 and 90 kg (inclusive) and the body mass index(BMI) between 18.0 and 27.0 (inclusive) * BMI(kg/m2) = Body weight (kg)/{height (m)}2 3. Voluntary consent to participation in this study and signature on the IRB-approved informed consent form after being explained about characteristics of this clinical study, prior to any screening test Exclusion Criteria: 1. Current or history of a clinically significant hepatic, renal, neurological, immunological, respiratory or endocrine disease or hematological or oncological disease, cardiovascular disease or psychiatric disease (mood disorder or compulsive disorder, etc.) (in case of a hepatic disease, a hepatitis virus-infected subject may be also included) 2. Hypersensitivity to a drug (aspirin or antibiotics, etc.) or past history of clinically significant hypersensitivity 3. In sitting vital signs measured after resting for 3 min or more, systolic blood pressure of \<90mmHg or \>150mmHg, or diastolic blood pressure of \<60mmHg or \>100 mmHg 4. Past history of drug abuse or positive urine drug screening results 5. Use of any prescription medicine or oriental medicine within 2 weeks or use of any over-the-counter(OTC) medication or vitamin preparation within 1 week prior to the scheduled first dose (however, a subject may be included if other conditions are satisfied, at the discretion of the investigator) 6. Participation in another clinical study and administration of a drug within 3 months prior to the scheduled first dose (from the dosing day) 7. Whole blood donation within 2 months or apheresis within 1 month prior to the scheduled first dose, or transfusion within 1 month prior to the first dose 8. A habitual drinker (\>21 units/week, 1 unit = 10 g of pure alcohol) or a person who cannot abstain from alcohol consumption during hospitalization 9. A smoker of 10 cigarettes/day on average over the past 3 months or a person who cannot abstain from smoking during hospitalization 10. A person who is planning to get pregnant during the study or who cannot practice acceptable contraception (example: surgical sterilization of a subject or a partner, intrauterine device used by a partner, barrier contraception, diaphragm or condom used in combination) even if not planning to get pregnant 11. Notable prolongation of the QT/QTcb interval at screening (e.g., repeated confirmation of QTcb interval \> 450 ms) 12. Confirmed history of a risk factor for TdP (e.g., heart failure, hypokalemia, family history of a long QT syndrome) 13. Chronic, uncontrolled or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosis) 14. Pyrexia of ≥38°C within 1 week prior to administration of the investigational product 15. Past history of tuberculosis infection and/or positive Quantiferon TB-Gold test results at screening 16. A person who had participated in this study and received the investigational product 17. A person who is otherwise determined as not eligible for clinical study participation by the investigator due to other reasons including clinical laboratory test results